<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M464</article-id>
      <article-id pub-id-type="publisher-id">molbank-2006-M464</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A one-step synthesis of pyrazolone</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Eller</surname>
            <given-names>Gernot A.</given-names>
          </name>
          <xref rid="c1-molbank-2006-M464" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holzer</surname>
            <given-names>Wolfgang</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2006-M464">Department of Drug Synthesis, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria; Phone: +43-1-4277-55634, e-mail: <email>gernot.eller@univie.ac.at</email></aff>
      <author-notes>
        <corresp id="c1-molbank-2006-M464"><label>*</label>Author to whom correspondence should be addressed</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>01</month>
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>01</month>
        <year>2006</year>
      </pub-date>
      <volume>2006</volume>
      <issue>1</issue>
      <elocation-id>M464</elocation-id>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>01</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>01</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2006 MDPI.</copyright-statement>
        <copyright-year>2006</copyright-year>
        <license>
          <p>All rights reserved.</p>
        </license>
      </permissions>
      <abstract>
        <p>The fully unsubstituted pyrazolone (= 2-pyrazolin-5-one, which is tautomer to 1<italic>H</italic>-pyrazol-3-ol and 1<italic>H</italic>-pyrazol-5-ol) was prepared from hydrazine hydrate and methyl (2<italic>E</italic>)-3-methoxyacrylate in almost quantitative yield. Detailed spectroscopic data (<sup>1</sup>H NMR, <sup>13</sup>C NMR, <sup>15</sup>N NMR, MS) for this compound are presented.</p>
      </abstract>
      <kwd-group>
        <kwd>Pyrazolone</kwd>
        <kwd>cyclization</kwd>
        <kwd>NMR spectroscopy</kwd>
        <kwd>tautomerism</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
      <p>Substituted 2-pyrazolin-5-ones play an important role as substructures of numerous pharmaceuticals, agrochemicals, dyes, pigments, as well as chelating agents and thus attract remarkable attention [<xref ref-type="bibr" rid="B1-molbank-2006-M464">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2006-M464">2</xref>]. </p>
      <p>Recently, we investigated the synthesis of some N1-unsubstituted pyrazolones by use of the PMB (<italic>p</italic>-methoxybenzyl) protecting group [<xref ref-type="bibr" rid="B3-molbank-2006-M464">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2006-M464">4</xref>]. Although this substituent proved to be conveniently removable from various 4-substituted pyrazolones upon treatment with refluxing trifluoroacetic acid only poor results were obtained when the parent 1-PMB-pyrazolone (= 2-(4-methoxybenzyl)-2,4-dihydro-3<italic>H</italic>-pyrazol-3-one [<xref ref-type="bibr" rid="B3-molbank-2006-M464">3</xref>]) was subjected to these conditions. Even prolonged heating (1 week instead of 1 day) did not effect full deprotection (1 day ~ 15%, 2 days ~ 35%, 7 days ~ 75%; monitored by mean of <sup>1</sup>H NMR). Hence, there is need for other and more suitable methods for the synthesis of the unsubstituted pyrazolone <bold>1</bold>. </p>
      <p>With respect to the fact that other hitherto described syntheses of <bold>1</bold> are characterized by multi-step procedures and/or low yields [<xref ref-type="bibr" rid="B5-molbank-2006-M464">5</xref>,<xref ref-type="bibr" rid="B6-molbank-2006-M464">6</xref>], we report here an almost quantitative one-step preparation of the fully unsubstituted pyrazolone system from hydrazine hydrate and methyl (2<italic>E</italic>)-3-methoxyacrylate following an already known procedure for the synthesis of 1-alkyl pyrazolones [<xref ref-type="bibr" rid="B7-molbank-2006-M464">7</xref>] (<xref ref-type="scheme" rid="molbank-2006-M464-sch001">Scheme 1</xref>).</p>
      <p>A considerable number of studies deal with the prototropic tautomerism of pyrazolones [<xref ref-type="bibr" rid="B8-molbank-2006-M464">8</xref>]. </p>
      <p>Determination of the tautomeric composition of compound <bold>1</bold> is quite challenging as eight possible tautomeric forms have to be considered. This may also be a reason why in the Chemical Abstracts Service (CAS) references are cited for all possible tautomeric forms of compound <bold>1</bold> (<xref ref-type="fig" rid="molbank-2006-M464-f001">Figure 1</xref>) except for form <bold>E</bold>. From the signal multiplicities in the carbon NMR spectra tautomeric forms <bold>B</bold>, <bold>C</bold>, <bold>F</bold>, <bold>G</bold>, and <bold>H</bold> can be excluded. Moreover, the <sup>15</sup>N NMR chemical shifts found for compound <bold>1</bold> (&#x2013;126.5 ppm and &#x2013;192.0 ppm) rule out form <bold>A</bold>, as for this tautomer a much smaller chemical shift for the =CH&#x2013;<underline>N</underline>H&#x2013; atom has to be expected (for instance, in phenazone &#x2013; 1,5-dimethyl-2-phenyl-1,2-dihydro-3<italic>H</italic>-pyrazol-3-one &#x2013; which is structurally related to form <bold>A</bold> this atom exhibits a chemical shift of &#x2013;245.1 ppm [<xref ref-type="bibr" rid="B9-molbank-2006-M464">9</xref>]). The differentiation between forms <bold>D</bold> and <bold>E</bold> is not a trivial task. However, from comparison of the <sup>13</sup>C chemical shifts, the <sup>15</sup>N chemical shifts, the <sup>3</sup><italic>J</italic>(H,H) coupling constants, and the different <sup>13</sup>C,<sup>1</sup>H-coupling constants of <bold>1</bold> with those of the corresponding N-phenyl analogues (1-phenyl-1<italic>H</italic>-pyrazol-3-ol, 1-phenyl-1<italic>H</italic>-pyrazol-5-ol) [<xref ref-type="bibr" rid="B10-molbank-2006-M464">10</xref>,<xref ref-type="bibr" rid="B11-molbank-2006-M464">11</xref>] we assume that form <bold>D</bold> is predominating in DMSO-<italic>d</italic><sub>6</sub> solution. Nevertheless an additional contribution of other isomers (in minor amounts) can not be ruled out.</p>
      <p>Compound <bold>1</bold>: Under stirring, to a solution of 5.81 g (50 mmol) of methyl (2<italic>E</italic>)-3-methoxyacrylate in methanol (5 mL) was hydrazine hydrate (2.75 g, 55 mmol) added and the mixture was refluxed for 1h. Evaporation under reduced pressure to dryness gave 4.13 g (98%) of a slightly yellowish powder, pure according to <sup>1</sup>H NMR spectroscopy.</p>
      <p>Melting point: 160&#x2013;162 &#xB0;C, crystal modifications starting at ~140 &#xB0;C, (lit. [<xref ref-type="bibr" rid="B12-molbank-2006-M464">12</xref>] 162&#x2013;164 &#xB0;C).</p>
      <p><sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>, 28 &#xB0;C, numbering for 1<italic>H</italic>-pyrazol-3-ol = form <bold>D</bold>) [<xref ref-type="bibr" rid="B13-molbank-2006-M464">13</xref>]: &#x3B4;= 9.82 (br s, 2H, XH); 7.33 (d, <sup>3</sup><italic>J</italic><sub>(H5,H4)</sub>= 2.3 Hz, 1H, H5); 5.43 (d, <sup>3</sup><italic>J</italic><sub>(H4,H5)</sub>= 2.3 Hz, 1H, H4).</p>
      <p><sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>, 28 &#xB0;C, numbering for 1<italic>H</italic>-pyrazol-3-ol = form <bold>D</bold>) [<xref ref-type="bibr" rid="B13-molbank-2006-M464">13</xref>]: &#x3B4;= 161.0 (C3, <sup>2</sup><italic>J</italic><sub>(C3,H4)</sub>= 3.4 Hz, <sup>3</sup><italic>J</italic><sub>(C3,H5)</sub>= 9.2 Hz); 130.1 (C5, <sup>1</sup><italic>J</italic> = 184.0 Hz, <sup>2</sup><italic>J</italic><sub>(C5,H4)</sub>= 8.2 Hz); 89.3 (C4, <sup>1</sup><italic>J</italic> = 175.6 Hz, <sup>2</sup><italic>J</italic><sub>(C4,H5)</sub>= 8.7 Hz).</p>
      <p><sup>15</sup>N-NMR (50 MHz, DMSO-<italic>d</italic><sub>6</sub>, 294 K) [<xref ref-type="bibr" rid="B14-molbank-2006-M464">14</xref>]: &#x3B4;= &#x2013;126.5; &#x2013;192.0.</p>
      <p>MS (m/z, %) [<xref ref-type="bibr" rid="B15-molbank-2006-M464">15</xref>]: 84 (M<sup>+</sup>, 100); 55 (24).</p>
      <p>Elemental Analysis: Calculated for C<sub>3</sub>H<sub>4</sub>N<sub>2</sub>O (84.08): C, 42.86%; H, 4.80%; N, 33.32%. Found: C, 42.75%; H, 4.65%; N, 33.15%.</p>
  </body>
  <back>
    <app-group>
    <app id="app1-molbank-2006-M464">
       <title>Supplementary materials</title>
       <supplementary-material id="molbank-2006-M464-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2006-M464-s001-mod.mol">
	   <label>Supplementary File 1</label>
	   </supplementary-material>
	   <supplementary-material id="molbank-2006-M464-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2006-M464-s001.mol">
	   <label>Supplementary File 2</label>
	   </supplementary-material>
	</app>
	</app-group>
    <ref-list>
      <title>References and Notes:</title>
      <ref id="B1-molbank-2006-M464">
        <label>1.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Elguero</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <source>Comprehensive Heterocyclic Chemistry: Pyrazoles and their Benzo Derivatives</source>
          <volume>Vol. 5</volume>
          <person-group person-group-type="editor">
            <name>
              <surname>Katritzky</surname>
              <given-names>A. R.</given-names>
            </name>
            <name>
              <surname>Rees</surname>
              <given-names>C. W.</given-names>
            </name>
          </person-group>
          <publisher-name>Pergamon Press</publisher-name>
          <publisher-loc>Oxford</publisher-loc>
          <year>1984</year>
          <fpage>167</fpage>
          <lpage>303</lpage>
        </citation>
      </ref>
      <ref id="B2-molbank-2006-M464">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stanovnik</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Svete</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Product class 1: Pyrazoles</article-title>
          <source>Science of Synthesis</source>
          <year>2002</year>
          <volume>12</volume>
          <fpage>15</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="doi">10.1002/chin.200346258</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2006-M464">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eller</surname>
              <given-names>G. A.</given-names>
            </name>
            <name>
              <surname>Holzer</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <source>Heterocycles</source>
          <year>2004</year>
          <volume>63</volume>
          <fpage>2537</fpage>
          <lpage>2555</lpage>
        </citation>
      </ref>
      <ref id="B4-molbank-2006-M464">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Becker</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Eller</surname>
              <given-names>G. A.</given-names>
            </name>
            <name>
              <surname>Holzer</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <source>Synthesis</source>
          <year>2005</year>
          <fpage>2583</fpage>
          <lpage>2589</lpage>
        </citation>
      </ref>
      <ref id="B5-molbank-2006-M464">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Testa</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Fontanella</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <source>Farmaco</source>
          <year>1971</year>
          <volume>26</volume>
          <fpage>1017</fpage>
          <lpage>35</lpage>
        </citation>
      </ref>
      <ref id="B6-molbank-2006-M464">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dorn</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Zubek</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <source>J. Prakt. Chem.</source>
          <year>1971</year>
          <volume>313</volume>
          <fpage>1118</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1002/prac.19713130617</pub-id>
        </citation>
      </ref>
      <ref id="B7-molbank-2006-M464">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maywald</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Steinmetz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rack</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gotz</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gotz</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Henkelmann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
		  <comment>Aiscar Bayeto, PCT Int. Appl. WO 0031042 A2 2000 (<italic>Chem. Abstr.</italic>, 2000, 133, 4655)</comment>
        </citation>
      </ref>
      <ref id="B8-molbank-2006-M464">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holzer</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Hallak</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <source>Heterocycles</source>
          <year>2004</year>
          <volume>63</volume>
          <fpage>1311</fpage>
          <lpage>1334</lpage>
          <comment>and references cited therein</comment>
        </citation>
      </ref>
      <ref id="B9-molbank-2006-M464">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cizmarik</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lycka</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <source>Pharmazie</source>
          <year>1988</year>
          <volume>43</volume>
          <fpage>794</fpage>
          <lpage>795</lpage>
          <pub-id pub-id-type="pmid">3247370</pub-id>
        </citation>
      </ref>
      <ref id="B10-molbank-2006-M464">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holzer</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Kautsch</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Laggner</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Claramunt</surname>
              <given-names>R. M.</given-names>
            </name>
            <name>
              <surname>Perez-Torralba</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Alkorta</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Elguero</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <source>Tetrahedron</source>
          <year>2004</year>
          <volume>60</volume>
          <fpage>6791</fpage>
          <lpage>6805</lpage>
        </citation>
      </ref>
      <ref id="B11-molbank-2006-M464">
        <label>11.</label>
        <citation citation-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Sackus</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Holzer</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <comment>manuscript in preparation</comment>
        </citation>
      </ref>
      <ref id="B12-molbank-2006-M464">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lingens</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Schneider-Bernloehr</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <source>Liebigs Ann. Chem.</source>
          <year>1965</year>
          <volume>686</volume>
          <fpage>134</fpage>
          <lpage>144</lpage>
        </citation>
      </ref>
      <ref id="B13-molbank-2006-M464">
        <label>13.</label>
		<note><p>The spectrum was obtained on a Varian UnityPlus 300 spectrometer (299.95 MHz for <sup>1</sup>H, 75.43 MHz for <sup>13</sup>C). The center of the solvent signal was used as an internal standard which was related to TMS with &#x3B4; 2.49 ppm (<sup>1</sup>H NMR) and &#x3B4; 39.5 ppm (<sup>13</sup>C NMR).</p></note>
      </ref>
      <ref id="B14-molbank-2006-M464">
        <label>14.</label>
		<note><p>The spectrum was obtained on a Bruker Avance 500 spectrometer and was referenced against neat, external nitromethane (coaxial capillary). The signals were not unequivocally assigned to the N atoms.</p></note>
      </ref>
      <ref id="B15-molbank-2006-M464">
        <label>15.</label>
		<note><p>The spectrum was obtained on a Shimadzu QP 1000 instrument (EI, 70eV).</p></note>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p><italic>Sample Availability</italic>: Available from MDPI.</p>
      </fn>
    </fn-group>
    <sec sec-type="display-objects">
      <title>Figure and Scheme</title>
      <fig id="molbank-2006-M464-sch001" position="float">
        <object-id pub-id-type="pii">molbank-2006-M464-sch001_Scheme 1</object-id>
        <label>Scheme 1</label>
        <caption>
          <p>One-step procedure for the preparation of &#x2018;pyrazolone&#x2019; 1.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2006-M464-sch001.tif"/>
      </fig>
      <fig id="molbank-2006-M464-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Possible tautomeric forms of &#x2018;pyrazolone&#x2019; 1.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2006-M464-g001.tif"/>
      </fig>
    </sec>
  </back>
</article>
